Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Gerald Hoebarth"'
Publikováno v:
Journal of immunological methods. 512
A modified biotin-drug extraction and acid dissociation (BEAD) immunogenicity assay was developed to detect anti-drug-antibodies (ADA) against the human anti-FXIIa monoclonal antibody (mAb) drug, Garadacimab (previously called CSL312). Multiple strat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::64b60c1dc592980aeb866a8b9e4d3a2a
https://pubmed.ncbi.nlm.nih.gov/36526009
https://pubmed.ncbi.nlm.nih.gov/36526009
Autor:
Gerald Hoebarth, Peter Leidenmuehler, Veronika Ehrlich, Peter Turecek, Barbara Dietrich, Werner Hoellriegl, Herbert Gritsch, Alfred Weber, Tanja Ruthsatz, Marietta Turecek, Martin J. Wolfsegger
Publikováno v:
Blood. 128:4977-4977
Hemophilia A is a rare genetic bleeding disorder caused by missing or defective factor VIII (FVIII), a crucial factor in blood coagulation. Baxalta Innovations / Shire is currently developing SHP 826 (BAX 826), as the next generation EHL rFVIII repla
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::453b04f669026cc6b01944b1208a5ab6
https://doi.org/10.1182/blood.v128.22.4977.4977
https://doi.org/10.1182/blood.v128.22.4977.4977
Autor:
Alexander Bauer, Peter Leidenmuehler, Karima Benamara, Gerald Hoebarth, Peter Turecek, Werner Hoellriegl, Martin J. Wolfsegger, Alexandra Kopić, Marietta Turecek
Publikováno v:
Blood. 128:2590-2590
To support the BAX 604 (FEIBA STAR) clinical study assessing different infusion rates and low volume reconstitution, the following nonclinical program was initiated: Two studies were performed in normal rats and FVIII-inhibited rabbits to evaluate th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1a18c02c8fc004f7f89e5dc603b8088c
https://doi.org/10.1182/blood.v128.22.2590.2590
https://doi.org/10.1182/blood.v128.22.2590.2590
Autor:
Marietta Putz, Paolo Rossato, Friedrich Scheiflinger, Herbert Gritsch, Peter Turecek, Alexandra Schiviz, Hanspeter Rottensteiner, Martin J. Wolfsegger, Gerald Hoebarth, Alfred L. Weber, Werner Hoellriegl
Publikováno v:
Blood. 126:1073-1073
Factor VIII (FVIII) is a critical component of the intrinsic coagulation pathway. Plasma-derived or recombinant (r) FVIII concentrates are used in patients with hemophilia A to provide a FVIII level sufficient to treat and prevent bleeding episodes.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::32f97d83b1e6f4a53b08ffe274214365
https://doi.org/10.1182/blood.v126.23.1073.1073
https://doi.org/10.1182/blood.v126.23.1073.1073
Autor:
Herbert Gritsch, Susan Kubik, Hans Peter Schwarz, Eva-Maria Muchitsch, Martin J. Wolfsegger, Friedrich Scheiflinger, Hartmut J. Ehrlich, Alfred L. Weber, John-Philip Lawo, Gerald Hoebarth
Publikováno v:
Blood. 116:4655-4655
Abstract 4655 The purpose of these PK studies was to assess the pharmacokinetic profile of Baxter's rFVIIa in comparison with a commercially available rFVIIa after a single intravenous bolus injection at a target dose of 0.6 mg/kg BW in mice and rats
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::309055f834afe79e8304727ec5a6374c
https://doi.org/10.1182/blood.v116.21.4655.4655
https://doi.org/10.1182/blood.v116.21.4655.4655